IR@PKUHSC  > 北京大学第一临床医学院  > 临床药理研究所
学科主题临床医学
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor
He, Yuxian1,2,3; Xiao, Yonghong4; Song, Haifeng5; Liang, Qing6; Ju, Dan6; Chen, Xin6; Lu, Hong1; Jing, Weiguo1; Jiang, Shibo1; Zhang, Linqi2,3,7
刊名JOURNAL OF BIOLOGICAL CHEMISTRY
2008-04-25
DOI10.1074/jbc.M800200200
283期:17页:11126-11134
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biochemistry & Molecular Biology
研究领域[WOS]Biochemistry & Molecular Biology
关键词[WOS]VIRUS TYPE-1 INFECTION ; GCN4 LEUCINE-ZIPPER ; ENTRY INHIBITORS ; MEMBRANE-FUSION ; COILED-COIL ; GP41 CORE ; ENVELOPE GLYCOPROTEINS ; ATOMIC-STRUCTURE ; SALT BRIDGES ; PEPTIDES
英文摘要

Enfuvirtide (T20) is the first and only HIV-1 fusion inhibitor approved for clinical use, but it can easily induce drug resistance limiting its practical application. A novel anti-HIV peptide, termed sifuvirtide, was designed based on the three-dimensional structure of the HIV-1 gp41 fusogenic core conformation. Here we report its in vitro anti-HIV potency, its mechanism of action, as well as the results from Phase Ia clinical studies. We demonstrated that sifuvirtide inhibited HIV-1-mediated cell-cell fusion in a dose-dependent manner and exhibited high potency against infections by a wide range of primary and laboratory-adapted HIV-1 isolates from multiple genotypes with R5 or X4 phenotypes. Notably, sifuvirtide was also highly effective against T20-resistant strains. Unlike T20, sifuvirtide could efficiently block six-helix bundle formation in a dominant negative fashion. These results suggest that sifuvirtide has a different mechanism of action from that of T20. Phase Ia clinical studies of sifuvirtide (FS0101) in 60 healthy individuals demonstrated good safety, tolerability, and pharmacokinetic profiles. A single dose regimen( 5,10,20,30, and 40 mg) by subcutaneous injection once daily at abdominal sites was well tolerated without serious adverse events. Pharmacokinetic studies of single and multiple administration of sifuvirtide showed that its decay half-lives were 20.0 +/- 8.6 h and 26.0 +/- 7.9h, respectively. In summary, sifuvirtide has potential to become an ideal fusion inhibitor for treatment of HIV/AIDS patients, including those with HIV-1 strains resistant to T20.

语种英语
WOS记录号WOS:000255067400008
引用统计
被引频次:148[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/60016
专题北京大学第一临床医学院_临床药理研究所
作者单位1.New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA
2.FusoGen Pharmaceut Inc, Beijing 100016, Peoples R China
3.Chinese Acad Med Sci, Inst Pathogen Biol, AIDS Res Ctr, Beijing 100730, Peoples R China
4.Peking Union Med Coll, Beijing 100730, Peoples R China
5.Peking Univ, Inst Clin Pharmacol, Beijing 100083, Peoples R China
6.Acad Mil Med Sci, Beijing Inst Radiat Med, Beijing 100850, Peoples R China
7.Tsinghua Univ, Comprehens AIDS Res Ctr, Beijing 100084, Peoples R China
推荐引用方式
GB/T 7714
He, Yuxian,Xiao, Yonghong,Song, Haifeng,et al. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor[J]. JOURNAL OF BIOLOGICAL CHEMISTRY,2008,283(17):11126-11134.
APA He, Yuxian.,Xiao, Yonghong.,Song, Haifeng.,Liang, Qing.,Ju, Dan.,...&Zhang, Linqi.(2008).Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor.JOURNAL OF BIOLOGICAL CHEMISTRY,283(17),11126-11134.
MLA He, Yuxian,et al."Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor".JOURNAL OF BIOLOGICAL CHEMISTRY 283.17(2008):11126-11134.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[He, Yuxian]的文章
[Xiao, Yonghong]的文章
[Song, Haifeng]的文章
百度学术
百度学术中相似的文章
[He, Yuxian]的文章
[Xiao, Yonghong]的文章
[Song, Haifeng]的文章
必应学术
必应学术中相似的文章
[He, Yuxian]的文章
[Xiao, Yonghong]的文章
[Song, Haifeng]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。